StockData
Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc. (HEPA) stock

HEPAOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as CTRVP
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q/A on Nov 17, 2026Score 1/30
$0.10−0.00 (-1.45%)

Close on Oct 19, 2026Market cap $7.26MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$7.26M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$7.30M
EPS, diluted
-$0.88
Book value per share
-$0.06
Diluted shares
71M

Trading

Previous close
$0.10
Open
$0.10
Day's range
$0.10 – $0.11
Volume
18,391
Average volume (20 days)
45,124

Market cap history

Month-end market cap since 2014, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodHEPAS&P 500DifferenceHEPA per yearS&P 500 per year
1 month+32.8%+0.6%+32.1 pts
3 months+67.4%+3.4%+64.0 pts
Year to date+70.2%+13.3%+56.9 pts
1 year+43.8%+16.6%+27.2 pts
3 years-100.0%+86.4%−186.3 pts-92.3%+23.1%
5 years-100.0%+81.9%−181.8 pts-85.4%+12.7%
10 years-100.0%+318.9%−418.9 pts-80.4%+15.4%

Twelve years at a glance

Fiscal years 2013 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$4.17M

Net income

-$7.30M

EPS, diluted

–

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Hepion Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Hepion Pharmaceuticals

Pharmaceutical Preparations

Hepion Pharmaceuticals, Inc. operates as a medical diagnostic company focused on diagnostic solutions. The company previously concentrated on developing drug therapies for chronic liver conditions, specifically its cyclophilin inhibitor rencofilstat, before divesting all related patent assets, clinical data, and drug materials. Currently, Hepion in-licenses diagnostic tests covering conditions such as celiac disease, respiratory multiplex infections, Helicobacter pylori, and hepatocellular carcinoma, alongside licensed liver disease diagnostic assets. It targets healthcare markets seeking clinical diagnostic tools.

Company profile, executives and history

Hepion Pharmaceuticals stock: common questions

What is Hepion Pharmaceuticals's stock price?

HEPA closed at $0.10 on Oct 19, 2026, down 1.45% on the day.

What is Hepion Pharmaceuticals's market cap?

Hepion Pharmaceuticals was worth $7.26M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is HEPA's P/E ratio?

Hepion Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$0.88), so it has no meaningful P/E ratio.

Does Hepion Pharmaceuticals pay a dividend?

No. Hepion Pharmaceuticals has not paid a cash dividend over the last twelve months.

How has HEPA stock performed over the past year?

Including dividends, HEPA returned +43.8% over the past year, against +16.6% for the S&P 500.

Who are Hepion Pharmaceuticals's competitors?

Companies most similar to Hepion Pharmaceuticals by business, industry and size include JAGX, ONCO, RDHL, MDGL, EOCN.

See a number that looks wrong?